Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives | Zendy

Hodowanec Aimee C. | Zendy; Pikis Andreas | Zendy; Komatsu Takashi E. | Zendy; Sampson Mario R. | Zendy; Younis Islam R. | Zendy; O'Rear Julian J. | Zendy; Singer Mary E. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

Author(s) -

Hodowanec Aimee C.,

Pikis Andreas,

Komatsu Takashi E.,

Sampson Mario R.,

Younis Islam R.,

O'Rear Julian J.,

Singer Mary E.

Publication year - 2019

Publication title -

the journal of clinical pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.92

H-Index - 116

eISSN - 1552-4604

pISSN - 0091-2700

DOI - 10.1002/jcph.1363

Subject(s) - cytomegalovirus , medicine , cytomegalovirus infection , intensive care medicine , disease , immunology , hematopoietic cell , human immunodeficiency virus (hiv) , haematopoiesis , human cytomegalovirus , stem cell , viral disease , virus , herpesviridae , biology , genetics

This review summarizes the significant impact of cytomegalovirus (CMV) infection on solid organ and hematopoietic stem cell transplant recipients. A discussion of the various CMV prevention and treatment strategies is provided, including a detailed description of each of the available CMV antiviral drugs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research